Toxicity Derived from Interaction between Natural Compounds and Cancer Therapeutic Drugs Metabolized by CYP3A4: Lessons Learned from Two Clinical Case Reports

Int J Mol Sci. 2023 Nov 5;24(21):15976. doi: 10.3390/ijms242115976.

Abstract

The use of natural compounds and, in general, the use of Complementary and Alternative Medicine (CAM), is growing steadily worldwide, both due to commercial pressure and the increasing use of self-medication and the desire to manage one's own personal health and well-being. Patients facing a cancer diagnosis are also strongly pressured to use these compounds, which are often added to standard therapeutic regimens, that should instead be based solely on diagnostic and therapeutic care pathways (DTCP) or evidence-based medicine (EBM). This study presents two clinical cases of cancer patients who presented to the pharmaceutical consultation service (PCD-Pharmacy Clinical Desk) established at the CRO Institute in Aviano, Italy. Both patients were using natural products along with prescribed chemotherapy. In the first case, a 55-year-old woman diagnosed with bilateral breast cancer with bone metastases, who was using natural compounds based on diosmin, escin (or aescin) and resveratrol in combination with ribociclib anticancer therapy, a severe ADR (neutropenia) was identified as a consequence of the drug-natural product interaction. In the second case, following a detailed medication review by the PCD, we avoided taking a therapeutic treatment (with natural compounds) that in itself could potentially render chemotherapy ineffective in a 57-year-old woman with multiple infiltrating ductal carcinoma of the left breast; the patient was planning to take a natural product containing St. John's Wort tincture and lemon balm tincture, in combination with paclitaxel and trastuzumab. In addition, we describe the corrective actions taken, thus outlining the main objectives of the activity of the PCD's pharmacy counseling service: first, to identify, report, and manage adverse drug reactions (ADRs), and second, to identify therapeutic combinations that present potential risks of toxicity or ineffectiveness of the drug therapy itself.

Keywords: CAM—complementary and alternative medicine; CYP3A4; interactions; natural compounds; toxicity.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Biological Products* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Complementary Therapies*
  • Cytochrome P-450 CYP3A
  • Drug Interactions
  • Drug-Related Side Effects and Adverse Reactions*
  • Escin
  • Female
  • Humans
  • Hypericum*
  • Middle Aged

Substances

  • Cytochrome P-450 CYP3A
  • Antineoplastic Agents
  • Biological Products
  • Escin
  • CYP3A4 protein, human